Lights and shadows of the actual European guidelines on bioanalytical method validation: the case of raltegravir

Therapeutic Drug Monitoring

Volumn 36, Issue 6, 2014, Pages 739-745

  Baldelli, Sara ^a,b   Cattaneo, Dario ^a,b   Fucile, Serena ^a,b   Clementi, Emilio ^a,c  

^a CNR   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SCIENTIFIC INSTITUTE   (Italy)

Author keywords

international guidelines; LC MS MS; raltegravir; validation

Indexed keywords

DRUG METABOLITE; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; EUROPEAN MEDICINES AGENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; PRACTICE GUIDELINE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; BLOOD; EUROPE; STANDARDS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EUROPE; GUIDELINES AS TOPIC; HUMANS; PYRROLIDINONES; TANDEM MASS SPECTROMETRY;

EID: 84930087775     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000083     Document Type: Article

References (20)

1. Taylor P. Matrix effects: the Achilles heel of quantitative highperformance liquid chromatography-electrospray-Tandem mass spectrometry. Clin Biochem. 2005; 38: 328-334
2. Vogeser M, Seger C. Pitfalls associated with the use of liquid chromatography-Tandem mass spectrometry in the clinical laboratory. Clin Chem. 2010; 56: 1234-1244
3. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci. 1992; 81: 309-312
4. Rocci ML Jr, Devanarayan V, Haughey DB, et al. Confirmatory reanalysis of incurred bioanalytical samples. AAPS J. 2007; 9: E336-E343
5. European Medicines Agency. Guideline on bioanalytical method validation, 2011. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf. Accessed November 2012
6. Brainard DM, Wenning LA, Stone JA, et al. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol. 2011; 51: 1376-1402
7. Jourdil JF, Bartoli M, Stanke-Labesque F. Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 3734-3738
8. Fayet A, Béguin A, Zanolari B, et al. A LC-Tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 1057-1069
9. Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant. 2001; 15: 402-409
10. Martin RF. General Deming regression for estimating systematic bias and its confidence interval in method-comparison studies. Clin Chem. 2000; 46: 100-104
11. Van Dobben de Bruyn CS. Cumulative sum tests: theory and practice. In: Griffin K, ed. Statistics. New York, NY: Hafner; 1968: 1-45
12. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1: 307-310
13. Cattaneo D, Ripamonti D, Baldelli S, et al. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010; 32: 782-786
14. van den Ouweland JM, Kema IP. The role of liquid chromatography-Tandem mass spectrometry in the clinical laboratory. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 883: 18-32
15. Crotti S, Seraglia R, Traldi P. Some thoughts on electrospray ionization mechanisms. Eur J Mass Spectrom (Chichester, Eng). 2011; 17: 85-99
16. Saint-Marcoux F, Sauvage FL, Marquet P. Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem. 2007; 388: 1327-1349
17. Wallemacq P. Mass spectrometry in laboratory medicine: when hightech meets routine needs. Clin Biochem. 2011; 44: 2-3
18. DeSilva B, Garofolo F, Rocci M, et al. 2012 White paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis. 2012; 4: 2213-2226
19. Baranczewski P, Stanczak A, Kautiainen A, et al. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol Rep. 2006; 58: 341-352
20. Vogeser M, Zachovar R, Spohrer U, et al. Potential lack of specificity using electrospray tandem-mass spectrometry for the analysis of mycophenolic acid in serum. Ther Drug Monit. 2001; 23: 722-724